Chattem’s Dexatrim Looks For Cost-Conscious Consumers Unfriendly To Alli

Chattem has not delivered a counter-punch to GlaxoSmithKline's alli, but the firm sees its Dexatrim supplement as "the only one left standing" to compete in the nonprescription weight-loss product category